Delcath Systems, Inc.

NasdaqCM DCTH

Delcath Systems, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024: 87.46%

Delcath Systems, Inc. Gross Profit Margin is 87.46% for the Trailing 12 Months (TTM) ending September 30, 2024, a 29.34% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Delcath Systems, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2023 was 67.62%, a -21.55% change year over year.
Delcath Systems, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was 86.20%, a 39.60% change year over year.
Delcath Systems, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was 61.75%, a 8.44% change year over year.
Delcath Systems, Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 56.94%, a -3.94% change year over year.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqCM: DCTH

Delcath Systems, Inc.

CEO	Mr. Gerard J. Michel MBA, MS
IPO Date	May 3, 2018
Location	United States
Headquarters	1633 Broadway
Employees	76
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Key trends

Past 5 years